Squalene epoxidase encoded by ERG1 affects morphogenesis and drug susceptibilities of Candida albicans
Open Access
- 21 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (6) , 905-913
- https://doi.org/10.1093/jac/dki112
Abstract
Objectives: Functional characterization of the erg1 mutant of ergosterol biosynthesis of Candida albicans. Methods: We disrupted the ERG1 gene of C. albicans, which encodes squalene epoxidase (EC 1.14.99.7). Since the disruption of both alleles of ERG1 was lethal, the second allele of a heterozygous disruptant was placed under the control of a regulable promoter, MET3p, which is repressed by methionine and cysteine. Results: The reverse-phase HPLC analysis of sterol, extracted from the conditional mutant strain, showed a total lack of ergosterol and instead accumulation of squalene. This imbalance in sterol composition led to defects in growth and increased susceptibilities to drugs including fluconazole, ketoconazole, cycloheximide, nystatin, amphotericin B and terbinafine. Reduced drug efflux activity of the erg1 mutant was associated with poor surface localization of Cdr1p, suggesting that enhanced passive diffusion and reduced efflux mediated by the ABC (ATP binding cassette) transporter Cdr1p increases drug susceptibility. Additionally, conditional erg1 mutant strains were unable to form hyphae in various media. Conclusions: Taken together, our results demonstrate that the absence of ergosterol, which is one of the constituents of membrane microdomains (rafts), has a direct effect on drug susceptibility and morphogenesis of C. albicans.Keywords
This publication has 36 references indexed in Scilit:
- Membrane Sphingolipid-Ergosterol Interactions Are Important Determinants of Multidrug Resistance in Candida albicansAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Low-Level Resistance to Azoles in Candida albicans Is Associated with Changes in Membrane Lipid Fluidity and AsymmetryAntimicrobial Agents and Chemotherapy, 2002
- Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequencesThe Lancet Infectious Diseases, 2002
- Drug resistance in yeasts — an emerging scenarioPublished by Elsevier ,2002
- Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strainsFEMS Microbiology Letters, 2000
- Multiple Resistant Phenotypes of Candida albicans Coexist during Episodes of Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 1999
- The yeast multidrug resistance pump, Pdr5p, confers reduced drug resistance in erg mutants of Saccharomyces cerevisiaeMicrobiology, 1999
- Resistance to fluconazole and amphotericin in Candida albicans from AIDS patientsThe Lancet, 1996
- Sterols inCandida AlbicansMutants Resistant to Polyene or Azole Antifungals, and of a Double MutantC. ALBICANS6.4CRC Critical Reviews in Microbiology, 1987
- The Lipid Composition of Azole-sensitive and Azole-resistant Strains of Candida albicansMicrobiology, 1986